Ignite Creation Date:
2024-05-06 @ 3:57 PM
Last Modification Date:
2024-10-26 @ 2:00 PM
Study NCT ID:
NCT04816123
Status:
COMPLETED
Last Update Posted:
2021-03-25
First Post:
2021-03-24
Brief Title:
The Mass Balance and Biotransformation of 14CDonafenib in Healthy Adult Man
Sponsor:
Suzhou Zelgen Biopharmaceuticals CoLtd
Organization:
Suzhou Zelgen Biopharmaceuticals CoLtd
Study Overview
Official Title:
The Mass Balance and Biotransformation Study of 14C Donafenib in Chinese Healthy Adult Male Volunteers
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to evaluate the mass balance and biotransformation after single-dose of 14CDonafenib orally in Chinese healthy adult male volunteers revealing the overall pharmacokinetic characteristics of Donafenib in humans and providing a reference for the rational administration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None